NAPSRx /
CNPR
/ /
exam
/ /
(Revised
/ /
18th
/ /
Edition)
/ /
questions with correct answers
/ // // //
what //does //a //STAT //order //mean? //- //verified //answer(s)-
✔✔a //drug //needed //immediately //and //given //only //once
what /
/information //does //the //overdosage //section //of //the //labeling //provide? //- //verified //answer(s)-
✔✔signs, //symptoms //and //treatment //of //acute //overdoses
types //of //drug-drug //interactions: //- //verified //answer(s)-
✔✔duplication, //opposition //(antagonism) //and //alteration //(p.51)
tolerance //vs //resistance //- //verified //answer(s)-
✔✔tolerance /
/is /
/the //diminished //response //to //a //drug; //resistance //is //the //cells //ability //to //resist //the //effects //of
//the //drug //on //them.
abbreviated //new //drug //application //(ANDA) //- //verified //answer(s)-
✔✔the /
, /process /
/by /
/which /
/applicants /
/must /
/scientifically /
/demonstrate /
/to //the //FDA //that //their //generic //product //is //bioequivalent //to //or //performs //in //the //same //way
//as //the //innovator //drug, //no //duplicate //testing //(p. //75)
the //Hatch-Waxman //Act //of //1984 //- //verified //answer(s)-✔✔-
A.K.A. //Drug //Price //Competition //and //Patent //Restoration //Act
-
made /
/it /
/easier /
/to /
/bring /
/generic /
/drugs /
/to /
/the /
/market /
/by /
/requiring //the //FDA //to //only //look //at //bioavailability //studies //in //order //to //approve //an //ANDA.
-gave //protection //to //the //research //based //manufacturers //by //providing //a //30-
month /
/automatic /
/cooling //off //period //once //an //ANDA //is //challenged //for //patent //infringement //(p. //75)
four //basic //transport //mechanisms //- //verified //answer(s)-
✔✔passive //diffusion, //facilitated //diffusion, //active //transport, //and //pinocytosis //(p. //95)
CNPR
/ /
exam
/ /
(Revised
/ /
18th
/ /
Edition)
/ /
questions with correct answers
/ // // //
what //does //a //STAT //order //mean? //- //verified //answer(s)-
✔✔a //drug //needed //immediately //and //given //only //once
what /
/information //does //the //overdosage //section //of //the //labeling //provide? //- //verified //answer(s)-
✔✔signs, //symptoms //and //treatment //of //acute //overdoses
types //of //drug-drug //interactions: //- //verified //answer(s)-
✔✔duplication, //opposition //(antagonism) //and //alteration //(p.51)
tolerance //vs //resistance //- //verified //answer(s)-
✔✔tolerance /
/is /
/the //diminished //response //to //a //drug; //resistance //is //the //cells //ability //to //resist //the //effects //of
//the //drug //on //them.
abbreviated //new //drug //application //(ANDA) //- //verified //answer(s)-
✔✔the /
, /process /
/by /
/which /
/applicants /
/must /
/scientifically /
/demonstrate /
/to //the //FDA //that //their //generic //product //is //bioequivalent //to //or //performs //in //the //same //way
//as //the //innovator //drug, //no //duplicate //testing //(p. //75)
the //Hatch-Waxman //Act //of //1984 //- //verified //answer(s)-✔✔-
A.K.A. //Drug //Price //Competition //and //Patent //Restoration //Act
-
made /
/it /
/easier /
/to /
/bring /
/generic /
/drugs /
/to /
/the /
/market /
/by /
/requiring //the //FDA //to //only //look //at //bioavailability //studies //in //order //to //approve //an //ANDA.
-gave //protection //to //the //research //based //manufacturers //by //providing //a //30-
month /
/automatic /
/cooling //off //period //once //an //ANDA //is //challenged //for //patent //infringement //(p. //75)
four //basic //transport //mechanisms //- //verified //answer(s)-
✔✔passive //diffusion, //facilitated //diffusion, //active //transport, //and //pinocytosis //(p. //95)
